Cannabis Report
Lithium
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 8/16/2018 10:35:37 AM - Followers: 54 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

WARNING: 

A REVERSE SPLIT HAS OCCURRED!

Company description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001, known as Prexigebersen has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity. The company is in the process of amending the dosing protocols for the combination trial and adding a Decitabine cohort.


http://www.biopathholdings.com/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf 
 

The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully, because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive. Will the company apply for FDA acclerated status as interim testing is complete on 17 evaluable patients?

A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson but we are awaiting the FDA website comfirmation of same.

Patent protection for manufacturing their neutral lipid delivery system has been granted.

 
Bio-Path Holdings may also begin in 2018 phase 1 testing of their antisense drug Prexigebersen on certain types of uterine cancer. An IND using Prexigebersen for treatment resistent breast cancer may also occur.  Additionally, BPTH is initiating the development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected to occur in 2018. The third drug BP1003 which targets the Stat-3 protein, is expected to begin IND-enabling studies with a goal to enter first in-human trials in 2019 for treatment of pancreatic tumors.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there was some renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. At the present BPTH has no partnerships with drug manufacturers but if BPTH's delivery system and drugs continue to show promise partnerships are expected.

This link to the company website describes their delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 5+ million in cash.

 
Bio-Path Holdings does not manufacture their drugs but uses contractors, hence the need for partners.
 
BPTH is presently traded on the NASDAQ.

Here are links to articles on their drug technology:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/wp-content/uploads/2017/06/Published-Article-Evolution-of-Antisense-in-Oncology.pdf

http://www.biopathholdings.com/wp-content/uploads/2018/03/BPTH_Lancet_20180329.pdf

Analyst coverage:

Stonegate Capital target $11-14

http://stonegateinc.com/reports/BPTH_Update_June_2018.pdf


 
 
 
 
Cannabis Report
Lithium
BPTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4013   News: HOUSTON, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Bio-Path SJSTOCKSHARK 08/16/18 10:35:36 AM
#4012   BPTH is finally where PN said they were Brettj 08/15/18 07:50:13 PM
#4011   Thanks you two. I’ll be patiently waiting for tyburt 08/15/18 12:59:28 PM
#4010   I’ve been thinking about jumping in for quite tyburt 08/15/18 12:55:05 PM
#4009   Dmoffat, It was a pleasure to have you SJSTOCKSHARK 08/15/18 11:46:10 AM
#4008   If he raises funds through dilution again when dmoffat 08/15/18 11:37:00 AM
#4007   Ty, I continue to dollar cost average down. SJSTOCKSHARK 08/15/18 11:36:10 AM
#4006   Thanks SJ... what are your sentiments? tyburt 08/15/18 10:29:30 AM
#4005   2nd Q results: SJSTOCKSHARK 08/15/18 09:05:16 AM
#4004   The new slide presentation is great. SJSTOCKSHARK 08/11/18 06:49:50 PM
#4003   Here is the link: SJSTOCKSHARK 08/11/18 05:24:28 PM
#4002   Did anyone notice they rewrote the slide presentation? wordlender 08/11/18 11:47:53 AM
#4001   News https://finance.yahoo.com/news/bio-path-holdings-announce-second-1315007 SJSTOCKSHARK 08/08/18 09:31:58 AM
#4000   Crunch, I cannot argue with you regarding the SJSTOCKSHARK 08/06/18 03:26:58 PM
#3999   I agree with dmoffat I think we are mbcrunch 08/06/18 02:08:40 PM
#3998   It is less than 10 days until the SJSTOCKSHARK 08/06/18 10:37:22 AM
#3997   A year or so ago I asked if blairsoldman 08/01/18 11:30:06 AM
#3996   No news on the earnings report yet. SJSTOCKSHARK 08/01/18 11:15:09 AM
#3995   We will know where we stand in 15 days. SJSTOCKSHARK 07/31/18 10:52:58 PM
#3994   What if they closed the doors a month dmoffat 07/31/18 09:31:07 PM
#3993   It looks like my August dollar cost averaging SJSTOCKSHARK 07/31/18 08:44:15 PM
#3992   Tyburt, In three weeks will know if there SJSTOCKSHARK 07/26/18 07:54:29 PM
#3991   Thanks! I mean has it been diluted at tyburt 07/26/18 10:45:06 AM
#3990   So much for negotiating from a position of too simple 07/26/18 09:27:33 AM
#3989   tyburt, Yes it is now 11,341,000 versus 113,410,000. SJSTOCKSHARK 07/25/18 10:38:51 PM
#3988   What’s the current share structure for BPTH? Has tyburt 07/25/18 09:43:17 PM
#3987   The next announcement from BPTH needs to include dmoffat 07/25/18 05:20:50 PM
#3986   I really hope this is a stupid question, blairsoldman 07/25/18 02:27:02 PM
#3985   Runnin, I believe market cap requirement is only SJSTOCKSHARK 07/25/18 11:33:41 AM
#3984   At the time of this post, we are Pat Torney 07/25/18 10:12:41 AM
#3983   The silence of management at this point speaks Runninonempty 07/25/18 09:51:04 AM
#3982   I thought yesterday's closing market cap was bad SJSTOCKSHARK 07/24/18 07:18:34 PM
#3981   He at least deserves a big bonus with Pat Torney 07/24/18 11:27:09 AM
#3980   Silly question. Of COURSE he needs a raise blairsoldman 07/24/18 11:20:51 AM
#3979   Yesterday the market cap closed below 17 million. SJSTOCKSHARK 07/24/18 11:17:03 AM
#3978   Yep ! Something has got to give ! too simple 07/20/18 01:12:47 PM
#3977   We have news, but I don't consider it SJSTOCKSHARK 07/19/18 07:21:58 PM
#3976   We are roughly 30 days from PN being SJSTOCKSHARK 07/14/18 12:07:51 PM
#3975   ABUS blows through a 600 million market cap. SJSTOCKSHARK 07/12/18 07:24:20 PM
#3974   SJ, I like your reasons, and I think too simple 07/11/18 03:51:34 PM
#3973   Simple, I hope you are correct. I have SJSTOCKSHARK 07/11/18 11:37:25 AM
#3972   My wife thinks I am crazy . I too simple 07/11/18 10:34:04 AM
#3971   I have been wrong many times before, especially here. dmoffat 07/10/18 03:12:35 PM
#3970   Maybe this time you are wrong to think blairsoldman 07/10/18 01:53:54 PM
#3969   I have thought/hoped that many times in the dmoffat 07/10/18 11:19:58 AM
#3968   This company always operates in quite......period. SJSTOCKSHARK 07/10/18 11:16:03 AM
#3967   I have no idea why I think this too simple 07/10/18 09:49:13 AM
#3966   tyroneweaver 07/05/18 12:32:31 AM
#3965   What happened with the BYU lawyer and tyroneweaver 07/05/18 12:32:31 AM
#3964   I use to think everyone here was being Runninonempty 07/03/18 05:01:45 PM
PostSubject